At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRS Carpenter Technology
Pre-Mkt 06-08 05:53:23 EDT
483.60
-9.02
-1.83%
盘前483.21
-0.39-0.08%
04:00 EDT
High500.16Low480.70Vol614.87K
Open486.29D1 Closing492.62Amplitude3.95%
Mkt Cap24.09BTradable Cap23.45BTotal Shares49.82M
T/O299.56MT/O Rate1.27%Tradable Shares48.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
GlobeNewswire  ·  06-06 17:15
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
GlobeNewswire  ·  06-04
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Carpenter Technology Director Steven E. Karol disposes of 2,000 common shares worth $975,478.80
Reuters  ·  06-04
Carpenter Technology Director Steven E. Karol disposes of 2,000 common shares worth $975,478.80
Carpenter Technology director John Anastasio Hart disposes of 250 common shares worth $115,470.33
Reuters  ·  06-02
Carpenter Technology director John Anastasio Hart disposes of 250 common shares worth $115,470.33
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
GlobeNewswire  ·  06-01
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
GlobeNewswire  ·  06-01
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire  ·  05-31
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
GlobeNewswire  ·  05-30
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
prnewswire  ·  05-28
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
Navigating the Pitfalls of Offshore Trusts as CRS 2.0 Implementation Approaches
Deep News  ·  05-27
Navigating the Pitfalls of Offshore Trusts as CRS 2.0 Implementation Approaches
Carpenter Technology: This Stock Will Melt Up -- Barron's
Dow Jones  ·  05-23
Carpenter Technology: This Stock Will Melt Up -- Barron's
Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), Brambles (BMBLF)
TIPRANKS  ·  05-22
Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), Brambles (BMBLF)
Carpenter Technology: This Stock Will Melt Up -- Barrons.com
Dow Jones  ·  05-21
Carpenter Technology: This Stock Will Melt Up -- Barrons.com
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
prnewswire  ·  05-20
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
J.P. Morgan Remains a Buy on Carpenter Technology (CRS)
TIPRANKS  ·  05-19
J.P. Morgan Remains a Buy on Carpenter Technology (CRS)
Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  05-15
Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
GlobeNewswire  ·  05-14
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
GlobeNewswire  ·  05-14
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
GlobeNewswire  ·  05-14
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Trump's 'Gold Dome' Missile Defense Plan Could Cost $1.2 Trillion Over 20 Years, Report Finds
Deep News  ·  05-13
Trump's 'Gold Dome' Missile Defense Plan Could Cost $1.2 Trillion Over 20 Years, Report Finds

Introduction

Company Name.
Carpenter Technology
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--